Abstract
This study evaluates the incidence and prognostic impact of aberrant methylation of 25 tumor suppressor genes in 40 patients with RARS, a MDS subtype, by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay. Methylation of at least one gene was detected in 18 patients (45%). The genes methylated were CDKN2B (20%), RASSF1 (18%), RARB (10%), CDH13 (7.5%) and FHIT (5%). Patients with at least one methylated gene had a significantly shorter OS than patients without methylated genes. Aberrant methylation is a frequent event in patients with RARS as in patients with high-risk MDS appears to confer a worse prognosis.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acid Anhydride Hydrolases / genetics
-
Adult
-
Aged
-
Aged, 80 and over
-
Anemia, Refractory / genetics*
-
Anemia, Sideroblastic / genetics*
-
Cyclin-Dependent Kinase Inhibitor p15 / genetics
-
DNA Methylation*
-
Female
-
Humans
-
Kaplan-Meier Estimate
-
Male
-
Middle Aged
-
Multivariate Analysis
-
Neoplasm Proteins / genetics
-
Polymerase Chain Reaction
-
Prognosis
-
Receptors, Retinoic Acid / genetics
-
Tumor Suppressor Proteins / genetics*
Substances
-
CDKN2B protein, human
-
Cyclin-Dependent Kinase Inhibitor p15
-
Neoplasm Proteins
-
RASSF1 protein, human
-
Receptors, Retinoic Acid
-
Tumor Suppressor Proteins
-
fragile histidine triad protein
-
retinoic acid receptor beta
-
Acid Anhydride Hydrolases